On January 1, 2024, the HyBioComBone project officially commenced, marking a revolutionary step towards addressing challenges in treating large bone defects. These defects, stemming from trauma, infections, or tissue removal due to cancer, present a significant orthopedic challenge, often necessitating multiple surgical interventions and prolonged recovery periods. The project’s goal is to develop innovative biomimetic macroporous composites with multifunctional properties, tailored for bone regeneration
and revolutionary cancer treatment. Employing an interdisciplinary approach, the project will design composites with optimal mechanical strength and carefully tuned biodegradability, incorporating
interpenetrating network hydrogels, nanostructured bioglasses, and calcium phosphates with the addition of various ions. This innovative approach is expected to have a substantial impact on society, patients, and healthcare, enabling cost reduction in treatment and improving the quality of life for patients with large bone defects.
